M. Elmer

2.4k total citations · 2 hit papers
13 papers, 1.7k citations indexed

About

M. Elmer is a scholar working on Surgery, Physiology and Pathology and Forensic Medicine. According to data from OpenAlex, M. Elmer has authored 13 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Surgery, 4 papers in Physiology and 2 papers in Pathology and Forensic Medicine. Recurrent topics in M. Elmer's work include Nausea and vomiting management (10 papers), Anesthesia and Pain Management (7 papers) and Sympathectomy and Hyperhidrosis Treatments (2 papers). M. Elmer is often cited by papers focused on Nausea and vomiting management (10 papers), Anesthesia and Pain Management (7 papers) and Sympathectomy and Hyperhidrosis Treatments (2 papers). M. Elmer collaborates with scholars based in United States, Netherlands and Denmark. M. Elmer's co-authors include Kevin Horgan, Judith K. Evans, Ronald de Wit, Sant P. Chawla, Steven M. Grunberg, Alexandra D. Carides, Richard J. Gralla, Paul J. Hesketh, Fausto Roila and David Warr and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and European Journal of Cancer.

In The Last Decade

M. Elmer

13 papers receiving 1.7k citations

Hit Papers

The Oral Neurokinin-1 Antagonist Aprepitant for the Preve... 2003 2026 2010 2018 2003 2018 100 200 300 400 500
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. The Oral Neurokinin-1 Antagonist Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting: A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial in Patients Receiving High-Dose Cisplatin—The Aprepitant Protocol 052 Study Group
    2003 593 citations Paul J. Hesketh, Steven M. Grunberg et al. Journal of Clinical Oncology profile →
  2. Increasing Diversity in Clinical Trials: Overcoming Critical Barriers
    2018 465 citations Luther T. Clark, Laurence O. Watkins et al. Current Problems in Cardiology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
M. Elmer United States 10 1.1k 655 248 185 177 13 1.7k
Enzo Ballatori Italy 23 869 0.8× 375 0.6× 115 0.5× 249 1.3× 383 2.2× 78 1.6k
Reema Mody United States 30 1.0k 0.9× 243 0.4× 135 0.5× 64 0.3× 84 0.5× 113 2.7k
Sally Barbour United States 10 620 0.6× 307 0.5× 70 0.3× 155 0.8× 211 1.2× 21 1.1k
Nicholas Chiu United States 19 354 0.3× 175 0.3× 155 0.6× 101 0.5× 214 1.2× 54 971
J Bryant United Kingdom 20 244 0.2× 131 0.2× 253 1.0× 103 0.6× 127 0.7× 32 1.4k
Samuel Whittle Australia 24 310 0.3× 144 0.2× 228 0.9× 55 0.3× 77 0.4× 94 1.6k
Jane Burch United Kingdom 18 461 0.4× 137 0.2× 235 0.9× 157 0.8× 233 1.3× 29 1.5k
Thomas Andrews United States 23 732 0.7× 98 0.1× 177 0.7× 176 1.0× 91 0.5× 39 2.3k
E. Neugebauer Germany 21 752 0.7× 133 0.2× 119 0.5× 49 0.3× 200 1.1× 80 2.1k
Gregory P. Victorino United States 25 709 0.6× 170 0.3× 227 0.9× 39 0.2× 36 0.2× 124 2.0k

Countries citing papers authored by M. Elmer

Since Specialization
Citations

This map shows the geographic impact of M. Elmer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by M. Elmer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites M. Elmer more than expected).

Fields of papers citing papers by M. Elmer

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by M. Elmer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by M. Elmer. The network helps show where M. Elmer may publish in the future.

Co-authorship network of co-authors of M. Elmer

This figure shows the co-authorship network connecting the top 25 collaborators of M. Elmer. A scholar is included among the top collaborators of M. Elmer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with M. Elmer. M. Elmer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

13 of 13 papers shown
1.
Elmer, M., et al.. (2020). Evaluation of the Content Validity and Cross-Cultural Validity of the Study Participant Feedback Questionnaire (SPFQ). Therapeutic Innovation & Regulatory Science. 54(6). 1522–1533. 8 indexed citations
2.
Elmer, M., et al.. (2020). Amplifying the Voice of the Patient in Clinical Research: Development of Toolkits for Use in Designing and Conducting Patient-Centered Clinical Studies. Therapeutic Innovation & Regulatory Science. 54(6). 1489–1500. 12 indexed citations
3.
Clark, Luther T., Laurence O. Watkins, Ileana L. Piña, et al.. (2018). Increasing Diversity in Clinical Trials: Overcoming Critical Barriers. Current Problems in Cardiology. 44(5). 148–172. 465 indexed citations breakdown →
4.
5.
Wit, Ronald de, Jørn Herrstedt, Bernardo L. Rapoport, et al.. (2004). The oral NK(1) antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: a combined analysis of two randomised, placebo-controlled phase III clinical trials.. PubMed. 40(3). 403–10. 119 indexed citations
6.
Chawla, Sant P., Steven M. Grunberg, Richard J. Gralla, et al.. (2003). Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy‐induced nausea and vomiting. Cancer. 97(9). 2290–2300. 177 indexed citations
7.
Carides, A., Jay D. Pearson, Kevin Horgan, et al.. (2003). Functional relevance of antiemetic control. European Journal of Cancer. 39(10). 1395–1401. 50 indexed citations
8.
Cai, Beilei, M. Elmer, Celeste Lindley, et al.. (2003). Assessing the impact of chemotherapy-induced nausea and vomiting on patients' daily lives: a modified version of the Functional Living Index?Emesis (FLIE) with 5-day recall. Supportive Care in Cancer. 11(8). 522–527. 113 indexed citations
9.
Hesketh, Paul J., Steven M. Grunberg, Richard J. Gralla, et al.. (2003). The Oral Neurokinin-1 Antagonist Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting: A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial in Patients Receiving High-Dose Cisplatin—The Aprepitant Protocol 052 Study Group. Journal of Clinical Oncology. 21(22). 4112–4119. 593 indexed citations breakdown →
10.
Carides, A., et al.. (2003). 937 Superiority of aprepitant, an oral NK1 antagonist, over standard antiemetic therapy: Reducing the impact of nausea and vomiting on patients' daily lives. European Journal of Cancer Supplements. 1(5). S282–S282. 2 indexed citations
11.
Wit, Ronald de, Jørn Herrstedt, Bernardo L. Rapoport, et al.. (2003). Addition of the Oral NK1 Antagonist Aprepitant to Standard Antiemetics Provides Protection Against Nausea and Vomiting During Multiple Cycles of Cisplatin-Based Chemotherapy. Journal of Clinical Oncology. 21(22). 4105–4111. 116 indexed citations
12.
Wit, Ronald de, Jørn Herrstedt, Bernardo L. Rapoport, et al.. (2003). The oral NK1 antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy. European Journal of Cancer. 40(3). 403–410. 75 indexed citations
13.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Enzo Ballatori Breakdown of academic impact, for papers by Reema Mody Breakdown of academic impact, for papers by Sally Barbour Breakdown of academic impact, for papers by Nicholas Chiu Breakdown of academic impact, for papers by J Bryant Breakdown of academic impact, for papers by Samuel Whittle Breakdown of academic impact, for papers by Jane Burch Breakdown of academic impact, for papers by Thomas Andrews Breakdown of academic impact, for papers by E. Neugebauer Breakdown of academic impact, for papers by Gregory P. Victorino
Rankless by CCL
2026